Frequently asked questions

Short answers about visits, memory changes, treatment, research and caregiving.

Written by Dr. Neelum Aggarwal, MD, cognitive neurologist Last reviewed Sources cited Editorial policy

Visits and booking

Email [email protected] and the office will reply with how to book. Visits take place through Rush University Medical Center. This website cannot book appointments or see medical records.

It depends on your insurance plan. Check with your insurer, and ask the office when you get in touch.

If possible, yes. A family member or friend can describe changes you may not notice and help remember the plan.

A complete list of medicines and supplements, recent test results and scans, your glasses and hearing aids, and your questions written down.

No. The website can't give personal medical advice, and please don't send detailed health information by email or through the site. For questions about your own care, contact your doctor or care team. In an emergency, call 911.

Memory and diagnosis

Yes. Occasionally forgetting a name or misplacing things, then remembering later, is common. Memory loss that disrupts daily life is not a normal part of aging and should be evaluated.

MCI is a measurable decline in memory or thinking that is greater than expected for age, while a person can still manage daily life largely independently. Some people with MCI stay stable or improve; others go on to develop dementia.

Several blood tests that detect Alzheimer's-related changes have been cleared by the FDA since 2025 for adults who already have symptoms. They are used as part of a full evaluation, not as a stand-alone diagnosis or a screening test for people without symptoms.

APOE testing is recommended before starting anti-amyloid therapy because it affects the risk of side effects. For other purposes it is a personal decision that is best made with genetic counseling, because results can affect how you and your relatives think about risk.

Most people having a memory evaluation get brain imaging, usually an MRI, to look for strokes, other changes or problems that could explain symptoms. Your doctor will explain whether it is needed for you.

Treatment

They are FDA-approved antibody medicines that clear amyloid from the brain. They are for people with MCI or mild dementia due to Alzheimer's disease whose amyloid has been confirmed by testing, and they can modestly slow decline. They require regular MRI monitoring because of the risk of brain swelling or small bleeds (ARIA).

Since July 2026, the FDA has allowed lecanemab to be started with a weekly under-the-skin autoinjector that can be used at home, with a health care provider guiding at least the first two doses. IV infusions every two weeks remain an option.

No. They are only for early stages, and people with certain MRI findings, those taking anticoagulant blood thinners, or those with two copies of APOE ε4 face higher risks. Experts also disagree about how meaningful the benefit is. The decision should be shared and unhurried.

Supplements are not reviewed by the FDA for effectiveness the way prescription medicines are. Bring any supplement you take to your appointment to check it is safe with your other medicines.

Research and trials

Many kinds of people, including healthy volunteers, people with memory concerns, people with a diagnosis and care partners. Each study has its own eligibility rules.

Yes. Taking part is voluntary and you can leave at any time without affecting your regular care.

Not always. Many trials randomly assign some participants to a placebo so the results can be trusted. Ask the study team whether the treatment will be offered to everyone later.

ClinicalTrials.gov lists registered studies, and the Alzheimer's Association's TrialMatch service suggests studies that may fit you.

For families and care partners

Start gently and privately, focus on specific examples and on staying independent, and suggest a general check-up. Many families find the Alzheimer's Association's 24/7 Helpline (800-272-3900) helpful for planning these conversations.

Care partners are often part of visits. Sharing medical information requires the patient's permission, so ask about privacy forms and how to be listed as a contact.

The Alzheimer's Association runs a free 24/7 Helpline at 800-272-3900 and support groups. The National Institute on Aging's ADEAR Center (800-438-4380) offers free information.

Sources

  1. Alzheimer's Association. Mild cognitive impairment (MCI). View source (opens in a new tab)
  2. Palmqvist S, Whitson HE, Allen LA, et al. Alzheimer's Association clinical practice guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer's disease within specialized care settings. Alzheimers Dement. 2025;21(7):e70535. View source (opens in a new tab)
  3. NeurologyLive. FDA clears Roche's single-biomarker Elecsys pTau217 blood test for Alzheimer disease. August 24, 2026. View source (opens in a new tab)
  4. U.S. Food and Drug Administration. FDA approves treatment for adults with Alzheimer's disease (Kisunla, donanemab-azbt). July 2, 2024. View source (opens in a new tab)
  5. Alzheimer's Association. Alzheimer's Association welcomes FDA approval of Leqembi subcutaneous starter dose. July 13, 2026. View source (opens in a new tab)
  6. Cummings J, Apostolova L, Rabinovici GD, et al. Lecanemab: appropriate use recommendations. J Prev Alzheimers Dis. 2023;10(3):362-377. View source (opens in a new tab)
  7. Alzheimer's Association. TrialMatch: find Alzheimer's and dementia clinical studies. View source (opens in a new tab)

Worried about memory changes in you or someone you love?

Email [email protected] and the office will reply with how to book a visit with Dr. Aggarwal at Rush University Medical Center.